Staff at VA Palo Alto Health Care System successfully performed the first transcatheter tricuspid valve replacement (TTVR) in the VA, marking a significant advancement in heart care for Veterans. This innovative procedure offers hope to those suffering from severe tricuspid regurgitation, a condition where the tricuspid valve fails to close properly, causing blood to leak backward. Traditionally, Veterans with this diagnosis faced limited and risky options, particularly older patients or those with multiple health issues.

The new Edwards EVOQUE TTVR system provides a safer alternative by using a catheter to replace the damaged valve through a vein, avoiding the need for open-heart surgery. The first recipient of this treatment is recovering well and experiencing improvement, demonstrating the procedure’s potential. Dr. Kang emphasized that this advancement represents a major step forward in heart care for Veterans. The EVOQUE device received FDA approval in 2024 after studies indicated it could significantly alleviate symptoms and enhance patients’ quality of life. This breakthrough underscores the VA’s commitment to providing Veterans with access to the latest medical innovations and opens opportunities for more patients to benefit from this less invasive treatment option. Veterans should consult their cardiologists to explore this therapy.